Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Secukinumab in non-radiographic axial spondyloarthritis: subgroup analysis based on key baseline characteristics from a randomized phase III study, PREVENT

Fig. 4

Improvement in BASDAI score through week 16. *P < 0.0001, †P < 0.001, §P < 0.01 versus placebo. Data presented as MMRM through week 16. BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; CRP, C-reactive protein; LS, least squares; MMRM, mixed-effects model repeated measures; MRI, magnetic resonance imaging; N, total number of patients

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us